In conclusion, we have demonstrated significant in vitro protection and selection of CDD and MDR1 gene-modified hematopoietic cells utilizing a safety-improved 3rd generation lentiviral gene transfer system as a first step towards the concept of myeloprotective gene therapy in the context of AML and MDS treatment. Here, CDA is linked to myelodysplastic syndrome.